Marker Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview

Marker Therapeutics

21/03/2025 11:49

Marker Therapeutics Inc MRKR.OQ MRKR.O is expected to report resultson March 24 (estimated) for the period ending December 31 2024

The Houston Texas-based  company is expected to report revenue of $3.982 million, according to the mean estimate from 3 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Marker Therapeutics Inc is for a loss of 22 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Marker Therapeutics Inc is $8.00​, above​ its last closing price of $1.25. ​​​

This summary was machine generated March 21 at 11:49 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)